한글목차

세계 암 면역치료 시장 규모는 2034년까지 연평균 12.6%의 성장률을 기록할 것으로 예상됩니다.

암 발병률 증가와 암 면역요법 연구 증가가 시장 성장을 견인:

세계보건기구(WHO)가 2024년 2월 발표한 자료에 따르면, 암은 전 세계 주요 사망 원인으로 2022년 약 2,000만 명이 새로 암에 걸리고 900만 명 이상이 사망했습닌다. 인구 고령화와 증가로 인해 2040년에는 전 세계 암 환자 수가 2,800만 명을 넘어설 것으로 미국암협회(American Cancer Society, Inc.)는 예측하고 있습니다. 북미는 암 사망자 수와 신규 환자 수에서 세계 4위인 반면, 세계 최대 인구를 보유한 중국은 두 가지 비율 모두 세계에서 가장 높습니다. 전 세계적으로 술과 담배 사용량 증가, 식습관 변화, 운동 부족, 대기오염 등의 요인으로 인해 암 발병률은 앞으로 더욱 높아질 것으로 보입니다.

면역요법으로 대표되는 최신 암 치료는 최근 이 분야에 혁명을 일으켰습니다. 연구자들과 종양학자들을 흥분시키고 있는 치료법 중 하나가 바로 암 면역요법입니다. 수년간의 집중적인 연구 결과, 암 면역치료는 전 세계적으로 암 치료법으로 사용되고 있습니다. 예를 들어, 독일의 생물 의학 연구 기관인 바이오메드 엑스(BioMed X)와 일본 최대 제약사 오노약품공업은 2023년 12월에 새로운 공동 연구를 시작한다고 발표했습니다. 호중구의 항암 작용을 이용해 차세대 면역 치료제를 개발하는 것이 이 연구의 목적입니다. 이러한 점에서 이 시장의 성장을 촉진하는 주요 요인은 면역요법을 개선하는 방법에 대한 지속적인 연구와 암 치료를 위한 새로운 면역요법의 지속적인 개발이 될 것으로 보입니다.

세계 암 면역치료 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인 및 시장 기회 분석, 시장 규모 추정 및 예측, 각 부문별·지역별·주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
• 영향 분석
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• 공급망 분석
• 규제 프레임워크
• 신흥 시장과 메가트렌드
• Porter's Five Forces 분석
• PEST 분석

제4장 암 면역치료 시장 분석 : 기술별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추정과 예측
• 단클론항체
• 면역조절제
• 기타
  • 시장 규모 추정과 예측 : 지역별
  • 시장 점유율 : 지역별

제5장 암 면역치료 시장 분석 : 용도별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추정과 예측
• 폐암
• 유방암
• 대장암
• 악성 흑색종
• 전립선암
• 두경부암
• 난소암
• 췌장암
• 기타
  • 시장 규모 추정과 예측 : 지역별
  • 시장 점유율 : 지역별

제6장 암 면역치료 시장 분석 : 최종사용자별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추정과 예측
• 병원
• 암 연구 센터
• 클리닉
  • 시장 규모 추정과 예측 : 지역별
  • 시장 점유율 : 지역별

제7장 암 면역치료 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추정과 예측

제8장 북미의 암 면역치료 시장 분석

제9장 유럽의 암 면역치료 시장 분석

제10장 아시아태평양의 암 면역치료 시장 분석

제11장 라틴아메리카의 암 면역치료 시장 분석

제12장 중동 및 아프리카의 암 면역치료 시장 분석

제13장 기업 개요

• 경쟁 상황
• 전략적 전망
• F. Hoffmann-La Roche Ltd.
• Merck &Co., Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Bayer AG
• AstraZeneca
• Lilly
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• GSK plc
• Gilead Sciences, Inc.
• Amgen Inc.
• AbbVie Inc.
• Immunocore Ltd.
• Sanofi
• Takeda Pharmaceutical Company Limited.

제14장 결론과 제안

• Visiongain에 의한 결론
• 시장 진출 기업에 대한 제안

영문목차

The global Cancer Immunotherapy market is projected to grow at a CAGR of 12.6% by 2034

The Cancer Immunotherapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Prevalence of Cancer and Increasing Research in Cancer Immunotherapy are driving the Market Growth

Cancer is a major cause of death worldwide, accounting for about 20 million new cancer cases and over 9 million deaths in 2022, according to data released by the World Health Organisation in February 2024. By 2040, the American Cancer Society, Inc. projects that the global cancer burden would have increased to over 28 million cases due to present and anticipated population ageing and growth. North America is fourth in terms of cancer deaths and fourth in terms of new cases, whereas China, which has the greatest population in the world, has the highest global proportion of both. The cancer burden may rise in the future due to factors such increased alcohol and tobacco use, poor diet, physical inactivity, and air pollution in many different parts of the world.

Modern cancer treatments, such as those based on immunotherapy, have revolutionised the field in recent years. One such treatment that has greatly excited researchers and oncologists is cancer immunotherapy. Globally, cancer immunotherapy is being used as a treatment for cancer after years of intensive research. For instance, the German biomedical research institute BioMed X and one of the biggest pharmaceutical corporations in Japan, Ono Pharmaceutical Co., Ltd., announced in December 2023 the commencement of a new cooperative research initiative. Using neutrophils' anticancer properties to create next-generation immunotherapies is the aim of this research endeavour. Therefore, the primary driver propelling the growth of this market is the ongoing research into how to improve immunotherapy and the ongoing development of novel immunotherapies for the treatment of cancer.

Reimbursement Challenges, High Cost and Side-effects may Hamper Cancer Immunotherapy Growth

Healthcare providers, insurance companies, and national and local government organisations all around the world have faced difficulties in getting reimbursement for cancer immunotherapy treatments. Cancer immunotherapy is one of the priciest medications available, costing more than $100,000 per patient. This covers the price of medications, hospital stays, and multiple days of intensive care because many patients receiving cancer immunotherapy treatments have serious adverse effects.

The Keytruda maker, Merck, states that the out-of-pocket expenses for each infusion might vary from $1,000 to $1,950. However, this rate can still be excessively expensive for many patients. In the event that the patient has Medigap or Medicare Advantage (Part C), additional coverage may be obtained. The Keytruda treatment may potentially be completely covered, depending on the plan. In actuality, 41% of patients with Medicare Advantage Plans reported having no out-of-pocket costs, according to Merck. Patients in developing nations cannot afford the high cost of immunotherapy medications. One of the main obstacles facing businesses developing immunotherapy medications is high pricing. Thus, it is one of the main factors impeding this market's growth over the predicted period.

What Questions Should You Ask Before Buying a Market Research Report?

How is the cancer immunotherapy market evolving?

What is driving and restraining the cancer immunotherapy market?

How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each cancer immunotherapy submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading cancer immunotherapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the cancer immunotherapy projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of cancer immunotherapy projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the cancer immunotherapy market?

Where is the cancer immunotherapy market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Cancer Immunotherapy market today, and over the next 10 years:

Our 286-page report provides 117 tables, 189 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), impact of rising Cancer Immunotherapy prices and recent developments.

Segments Covered in the Report

Technology

Monoclonal Antibodies

Immunomodulators

Other Technology

Application

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Prostate Cancer

Head & Neck Cancer

Ovarian Cancer

Pancreatic Cancer

Others

End-users

Hospitals

Cancer Research Centres

Clinics

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Switzerland

Netherlands

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

South East Asia

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

MEA

GCC

South Africa

Egypt

Rest of MEA

The report also includes profiles for some of the leading companies in the Cancer Immunotherapy Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie Inc.

Amgen Inc.

AstraZeneca

Bayer AG

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GSK plc

Immunocore Ltd.

Johnson & Johnson Services, Inc.

Lilly

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

Sanofi

Takeda Pharmaceutical Company Limited

Overall world revenue for Cancer Immunotherapy Market, 2024 to 2034 in terms of value the market will surpass US$135.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Cancer Immunotherapy Market, 2024 to 2034 report help you?

In summary, our 280+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Cancer Immunotherapy Market, 2024 to 2034, with forecasts for technology, application, end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 25 key national markets - See forecasts for the Cancer Immunotherapy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, South East Asia, Argentina, GCC, South Africa, and Egypt among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 16 of the major companies involved in the Cancer Immunotherapy Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Cancer Immunotherapy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Cancer Immunotherapy Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
• 3.3 Impact Analysis
  • 3.3.1 Market Driving Factors
    • 3.3.1.1 Increasing Prevalence of Cancer
    • 3.3.1.2 Increasing Research in Cancer Immunotherapy
    • 3.3.1.3 Increasing Funding for the Cancer Research by Government, Public and Private Sector
  • 3.3.2 Market Restraining Factors
    • 3.3.2.1 Reimbursement Challenges for Cancer immunotherapy
    • 3.3.2.2 High Cost and Side-effects of Cancer Immunotherapy
  • 3.3.3 Market Opportunities
    • 3.3.3.1 Increased Focus towards Advanced Treatment Protocols
    • 3.3.3.2 Significant Unmet Need in Cancer Diagnosis
    • 3.3.3.3 Growing use of AI in Cancer immunotherapy Manufacturing
• 3.4 Supply Chain Analysis
• 3.5 Regulatory Framework
• 3.6 Emerging Markets and Megatrends
• 3.7 Porter's Five Forces Analysis
  • 3.7.1 Bargaining Power of Buyers (High)
  • 3.7.2 Bargaining Power of Suppliers (Low)
  • 3.7.3 Threat of New Entrants (Low)
  • 3.7.4 Threat of Substitute Products (High)
  • 3.7.5 Intensity of Competitive Rivalry (High)
• 3.8 PEST Analysis

4 Cancer Immunotherapy Market Analysis by Technology

• 4.1 Key Findings
• 4.2 Technology Segment: Market Attractiveness Index
• 4.3 Cancer Immunotherapy Market Size Estimation and Forecast by Technology
• 4.4 Monoclonal Antibodies
  • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.4.2 Market Share by Region, 2024 & 2034 (%)
• 4.5 Immunomodulators
  • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.5.2 Market Share by Region, 2024 & 2034 (%)
• 4.6 Other Technology
  • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Cancer Immunotherapy Market by Application

• 5.1 Key Findings
• 5.2 Application Segment: Market Attractiveness Index
• 5.3 Cancer Immunotherapy Market, by Application
• 5.4 Lung Cancer
  • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.4.2 Market Share by Region, 2024 & 2034 (%)
• 5.5 Breast Cancer
  • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.5.2 Market Share by Region, 2024 & 2034 (%)
• 5.6 Colorectal Cancer
  • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.6.2 Market Share by Region, 2024 & 2034 (%)
• 5.7 Melanoma
  • 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.7.2 Market Share by Region, 2024 & 2034 (%)
• 5.8 Prostate Cancer
  • 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.8.2 Market Share by Region, 2024 & 2034 (%)
• 5.9 Head & Neck Cancer
  • 5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.9.2 Market Share by Region, 2024 & 2034 (%)
• 5.10 Ovarian Cancer
  • 5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.10.2 Market Share by Region, 2024 & 2034 (%)
• 5.11 Pancreatic Cancer
  • 5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.11.2 Market Share by Region, 2024 & 2034 (%)
• 5.12 Others
  • 5.12.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.12.2 Market Share by Region, 2024 & 2034 (%)

6 Cancer Immunotherapy Market by End-users

• 6.1 Key Findings
• 6.2 End-users Segment: Market Attractiveness Index
• 6.3 Cancer Immunotherapy Market by End-users Forecast, 2024-2034
• 6.4 Hospitals
  • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.4.2 Market Share by Region, 2024 & 2034 (%)
• 6.5 Cancer Research Centers
  • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.5.2 Market Share by Region, 2024 & 2034 (%)
• 6.6 Clinics
  • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.6.2 Market Share by Region, 2024 & 2034 (%)

7 Cancer Immunotherapy Market Analysis by Region

• 7.1 Key Findings
• 7.2 Regional Market Size Estimation and Forecast

8 North America Cancer Immunotherapy Market Analysis

• 8.1 Key Findings
• 8.2 North America Cancer Immunotherapy Market Attractiveness Index
• 8.3 North America Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 8.4 North America Cancer Immunotherapy Market Size Estimation and Forecast by Country
• 8.5 North America Cancer Immunotherapy Market Size Estimation and Forecast by Technology
• 8.6 North America Cancer Immunotherapy Market Size Estimation and Forecast by Application
• 8.7 North America Cancer Immunotherapy Market Size Estimation and Forecast by End-users
• 8.8 U.S. Cancer Immunotherapy Market Analysis
• 8.9 Canada Cancer Immunotherapy Market Analysis

9 Europe Cancer Immunotherapy Market Analysis

• 9.1 Key Findings
• 9.2 Europe Cancer Immunotherapy Market Attractiveness Index
• 9.3 Europe Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 9.4 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Country
• 9.5 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Technology
• 9.6 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Application
• 9.7 Europe Cancer Immunotherapy Market Size Estimation and Forecast by End-users
• 9.8 Germany Cancer Immunotherapy Market Analysis
• 9.9 UK Cancer Immunotherapy Market Analysis
• 9.10 France Cancer Immunotherapy Market Analysis
• 9.11 Italy Cancer Immunotherapy Market Analysis
• 9.12 Spain Cancer Immunotherapy Market Analysis
• 9.13 Switzerland Cancer Immunotherapy Market Analysis
• 9.14 Netherlands Cancer Immunotherapy Market Analysis
• 9.15 Rest of Europe Cancer Immunotherapy Market Analysis

10 Asia Pacific Cancer Immunotherapy Market Analysis

• 10.1 Key Findings
• 10.2 Asia Pacific Cancer Immunotherapy Market Attractiveness Index
• 10.3 Asia Pacific Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 10.4 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Country
• 10.5 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Technology
• 10.6 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Application
• 10.7 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by End-users
• 10.8 Japan Cancer Immunotherapy Market Analysis
• 10.9 China Cancer Immunotherapy Market Analysis
• 10.10 India Cancer Immunotherapy Market Analysis
• 10.11 Australia Cancer Immunotherapy Market Analysis
• 10.12 South Korea Cancer Immunotherapy Market Analysis
• 10.13 South East Asia Cancer Immunotherapy Market Analysis
• 10.14 Rest of Asia Pacific Cancer Immunotherapy Market Analysis

11 Latin America Cancer Immunotherapy Market Analysis

• 11.1 Key Findings
• 11.2 Latin America Cancer Immunotherapy Market Attractiveness Index
• 11.3 Latin America Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 11.4 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Country
• 11.5 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Technology
• 11.6 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Application
• 11.7 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by End-users
• 11.8 Brazil Cancer Immunotherapy Market Analysis
• 11.9 Mexico Cancer Immunotherapy Market Analysis
• 11.10 Argentina Cancer Immunotherapy Market Analysis
• 11.11 Rest of Latin America Cancer Immunotherapy Market Analysis

12 MEA Cancer Immunotherapy Market Analysis

• 12.1 Key Findings
• 12.2 MEA Cancer Immunotherapy Market Attractiveness Index
• 12.3 MEA Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 12.4 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Country
• 12.5 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Technology
• 12.6 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Application
• 12.7 MEA Cancer Immunotherapy Market Size Estimation and Forecast by End-users
• 12.8 GCC Cancer Immunotherapy Market Analysis
• 12.9 South Africa Cancer Immunotherapy Market Analysis
• 12.10 Egypt Cancer Immunotherapy Market Analysis
• 12.11 Rest of MEA Cancer Immunotherapy Market Analysis

13 Company Profiles

• 13.1 Competitive Landscape, 2023
• 13.2 Strategic Outlook
• 13.3 F. Hoffmann-La Roche Ltd.
  • 13.3.1 Company Snapshot
  • 13.3.2 Company Overview
  • 13.3.3 Financial Analysis
    • 13.3.3.1 Net Revenue, 2019-2023
    • 13.3.3.2 R&D, 2019-2023
    • 13.3.3.3 Segment Market Shares, 2023
    • 13.3.3.4 Regional Market Shares, 2023
  • 13.3.4 Product Benchmarking
  • 13.3.5 Strategic Outlook
• 13.4 Merck & Co., Inc.
  • 13.4.1 Company Snapshot
  • 13.4.2 Company Overview
  • 13.4.3 Financial Analysis
    • 13.4.3.1 Net Revenue, 2019-2023
    • 13.4.3.2 R&D, 2019-2023
    • 13.4.3.3 Segment Market Shares, 2023
    • 13.4.3.4 Regional Market Shares, 2023
  • 13.4.4 Product Benchmarking
  • 13.4.5 Strategic Outlook
• 13.5 Novartis AG
  • 13.5.1 Company Snapshot
  • 13.5.2 Company Overview
  • 13.5.3 Financial Analysis
    • 13.5.3.1 Net Revenue, 2019-2023
    • 13.5.3.2 R&D, 2019-2023
    • 13.5.3.3 Segment Market Shares, 2023
    • 13.5.3.4 Regional Market Shares, 2023
  • 13.5.4 Product Benchmarking
  • 13.5.5 Strategic Outlook
• 13.6 Bristol-Myers Squibb Company
  • 13.6.1 Company Snapshot
  • 13.6.2 Company Overview
  • 13.6.3 Financial Analysis
    • 13.6.3.1 Net Revenue, 2019-2023
    • 13.6.3.2 R&D, 2019-2023
    • 13.6.3.3 Segment Market Shares, 2023
    • 13.6.3.4 Regional Market Shares, 2023
  • 13.6.4 Product Benchmarking
  • 13.6.5 Strategic Outlook
• 13.7 Bayer AG
  • 13.7.1 Company Snapshot
  • 13.7.2 Company Overview
  • 13.7.3 Financial Analysis
    • 13.7.3.1 Net Revenue, 2019-2023
    • 13.7.3.2 R&D, 2019-2023
    • 13.7.3.3 Segment Market Shares, 2023
    • 13.7.3.4 Regional Market Shares, 2023
  • 13.7.4 Product Benchmarking
  • 13.7.5 Strategic Outlook
• 13.8 AstraZeneca
  • 13.8.1 Company Snapshot
  • 13.8.2 Company Overview
  • 13.8.3 Financial Analysis
    • 13.8.3.1 Net Revenue, 2019-2023
    • 13.8.3.2 R&D, 2019-2023
    • 13.8.3.3 Segment Market Shares, 2023
    • 13.8.3.4 Regional Market Shares, 2023
  • 13.8.4 Product Benchmarking
  • 13.8.5 Strategic Outlook
• 13.9 Lilly
  • 13.9.1 Company Snapshot
  • 13.9.2 Company Overview
  • 13.9.3 Financial Analysis
    • 13.9.3.1 Net Revenue, 2019-2023
    • 13.9.3.2 R&D, 2019-2023
    • 13.9.3.3 Regional Market Shares, 2023
  • 13.9.4 Product Benchmarking
  • 13.9.5 Strategic Outlook
• 13.10 Pfizer Inc.
  • 13.10.1 Company Snapshot
  • 13.10.2 Company Overview
  • 13.10.3 Financial Analysis
    • 13.10.3.1 Net Revenue, 2019-2023
    • 13.10.3.2 R&D, 2019-2023
    • 13.10.3.3 Segment Market Shares, 2023
    • 13.10.3.4 Regional Market Shares, 2023
  • 13.10.4 Product Benchmarking
  • 13.10.5 Strategic Outlook
• 13.11 Johnson & Johnson Services, Inc.
  • 13.11.1 Company Snapshot
  • 13.11.2 Company Overview
  • 13.11.3 Financial Analysis
    • 13.11.3.1 Net Revenue, 2019-2023
    • 13.11.3.2 R&D, 2019-2023
    • 13.11.3.3 Segment Market Shares, 2023
    • 13.11.3.4 Regional Market Shares, 2023
  • 13.11.4 Product Benchmarking
  • 13.11.5 Strategic Outlook
• 13.12 GSK plc
  • 13.12.1 Company Snapshot
  • 13.12.2 Company Overview
  • 13.12.3 Financial Analysis
    • 13.12.3.1 Net Revenue, 2019-2023
    • 13.12.3.2 R&D, 2019-2023
    • 13.12.3.3 Segment Market Shares, 2023
    • 13.12.3.4 Regional Market Shares, 2023
  • 13.12.4 Product Benchmarking
  • 13.12.5 Strategic Outlook
• 13.13 Gilead Sciences, Inc.
  • 13.13.1 Company Snapshot
  • 13.13.2 Company Overview
  • 13.13.3 Financial Analysis
    • 13.13.3.1 Net Revenue, 2019-2023
    • 13.13.3.2 R&D, 2019-2023
    • 13.13.3.3 Segment Market Shares, 2023
    • 13.13.3.4 Regional Market Shares, 2023
  • 13.13.4 Product Benchmarking
  • 13.13.5 Strategic Outlook
• 13.14 Amgen Inc.
  • 13.14.1 Company Snapshot
  • 13.14.2 Company Overview
  • 13.14.3 Financial Analysis
    • 13.14.3.1 Net Revenue, 2019-2023
    • 13.14.3.2 R&D, 2019-2023
    • 13.14.3.3 Regional Market Shares, 2023
  • 13.14.4 Product Benchmarking
  • 13.14.5 Strategic Outlook
• 13.15 AbbVie Inc.
  • 13.15.1 Company Snapshot
  • 13.15.2 Company Overview
  • 13.15.3 Financial Analysis
    • 13.15.3.1 Net Revenue, 2019-2023
    • 13.15.3.2 R&D, 2019-2023
    • 13.15.3.3 Segment Market Shares, 2023
    • 13.15.3.4 Regional Market Shares, 2023
  • 13.15.4 Product Benchmarking
  • 13.15.5 Strategic Outlook
• 13.16 Immunocore Ltd.
  • 13.16.1 Company Snapshot
  • 13.16.2 Company Overview
  • 13.16.3 Financial Analysis
    • 13.16.3.1 Net Revenue, 2019-2023
    • 13.16.3.2 R&D, 2019-2023
    • 13.16.3.3 Regional Market Shares, 2023
  • 13.16.4 Product Benchmarking
  • 13.16.5 Strategic Outlook
• 13.17 Sanofi
  • 13.17.1 Company Snapshot
  • 13.17.2 Company Overview
  • 13.17.3 Financial Analysis
    • 13.17.3.1 Net Revenue, 2019-2023
    • 13.17.3.2 R&D, 2019-2023
    • 13.17.3.3 Segment Market Shares, 2023
    • 13.17.3.4 Regional Market Shares, 2023
  • 13.17.4 Product Benchmarking
  • 13.17.5 Strategic Outlook
• 13.18 Takeda Pharmaceutical Company Limited.
  • 13.18.1 Company Snapshot
  • 13.18.2 Company Overview
  • 13.18.3 Financial Analysis
    • 13.18.3.1 Net Revenue, 2019-2023
    • 13.18.3.2 R&D, 2019-2023
    • 13.18.3.3 Segment Market Shares, 2023
    • 13.18.3.4 Regional Market Shares, 2023
  • 13.18.4 Product Benchmarking
  • 13.18.5 Strategic Outlook

14 Conclusion and Recommendations

• 14.1 Concluding Remarks from Visiongain
• 14.2 Recommendations for Market Players